|Adjuvant Therapy Polychemotherapy||Short-Term Effects||Long-Term Effects|
|Anthracyclines||Progressive decrease in left ventricular function, often leading to overt heart failure|
|Aromatase inhibitors||Unknown at this time|
|Bevacizumab (not yet evaluated in the adjuvant breast cancer setting)|
↵⁎ The time-course (early vs. late effects) of cardiovascular risk associated with endocrine therapy, human epidermal growth factor receptor (HER)-2–directed therapies, and angiogenesis inhibitors has not been established given the relatively short period of time that these agents have been used in early breast cancer management.